— Where do these books ______?— Put them back...

–Where do these books _____?

--Put them back _____they were.

高三英语单项填空中等难度题查看答案及解析

— Where do these books ______?

— Put them back ______ they were.

A. go; where　　　　     B. lay; where　　　     C. lie; to where　　     D. place; to which

高三英语单项填空中等难度题查看答案及解析

. Put the books back _______ they belong after you have finished them.

高三英语单项填空简单题查看答案及解析

Don’t forget to put the tools back where they were after you have finished your work,　 　 　　 ?

A. do you　　 　 B.don't you

C. will you　　 D. won’t you

高三英语单项填空中等难度题查看答案及解析

. Put the book back to the same place ________ you found it after finishing reading.

A．where     B．that         C．as    D．which

高三英语单项填空简单题查看答案及解析

—Put these glasses away before they　　　　　　 ．

—OK．I'll put them in the cupboard．

A．have broken　　     B．are breaking　　　　         C．will be broken         D．get broken

高三英语单项填空中等难度题查看答案及解析

--- Put these glasses away before they __________．

--- OK．I will put them in the cupboard．

A．have broken       B．are breaking       C．get broken         D．will be broken

高三英语单项填空中等难度题查看答案及解析

— Put these glasses away before they______.

— OK, I’ll put them in the cupboard.

A. have broken      B. are breaking         C. get broken      D. will be broken

高三英语单项填空困难题查看答案及解析

“ New and improved. ” These words are put in so many marketing campaigns that we tend to accept them as linked. But many new drugs aren't an improvement over the best existing drug for a given condition, and the fast drug-approval processes in recent years have added to the uncertainty about their advantages.

A recent report in the British Medical Journal, "New Drugs: Where Did We Go Wrong and What Can We Do Better?, analysed the issue, The authors looked at 216 drugs approved between 2011 and 2017 ； 152 were newly developed, and 64 were existing medicine approved for new uses. Only 25% offered a major advantage over the established treatment, and fully 58% had no confirmed added benefit to reduce symptoms or improve health-related quality of life.

"This doesn’t mean there's no added benefit," lead author Wieseler said. “It just means we have no positive proof. Either we have no studies or have studies not good enough. ” Wieseler and her co-authors work for a German institute which evaluates new treatments and advises on whether the country's health care system should pay a premium ( 占)for them. Such organizations , known as health technology assessment ( HTA) agencies, work a little differently in the US, says Sean Tunis，a researcher in Baltimore: “ If payers think a new drug isn't better than an existing drug，these agencies will require .that hospitals try the cheaper drug first. ”

Germany's HTA demands trials to prove that a new treatment beats the existing standard. This isn't always practical For one thing, such studies can be expensive and time-consuming, with no guarantee of success. Secondly, it can discourage companies from attempting to develop new alternatives. This is already happening. Drug developers are increasingly focused on areas where there are no good treatments to compete with, such as rare diseases.

This lack of meaningful data to guide patients is a major point of Wieseler's paper- With accelerated approval, there are more products approved, with a greater amount of uncertainty about risks and benefits. But there are other solutions besides drug trials. One idea is to require postmarket studies to track the effectiveness of newly approved drugs—a step too often neglected.

1.What message does the recent report convey?

A.Many new drugs have no improved advantages.

B.The approval processes for new drugs are too fast.

C.Improved drugs have advantages over old ones.

D.Before 2017 no improvement was made to drugs.

2.What will US HTA agencies do when no advantage is found in new drugs?

A.Remove government premium on them.

B.Get hospitals to use the cheaper drugs.

C.Arrange financial support for the patients.

D.Put new drugs on further trials and studies.

3.What's the disadvantage of Germany's HTA trial demands?

A.Making drug companies think of illegal ways to cut cost.

B.Pushing companies to try alternatives for existing drugs.

C.Getting patients to depend on the government for support.

D.Holding companies back from improving existing drugs.

4.What is the best title for the text?

A.The Advantage of Existing Drugs

B.Misunderstanding of New and Old Drugs

C.A Dilemma with New Drug Alternatives

D.Peopled Preference for New or Old Drugs

高三英语阅读理解中等难度题查看答案及解析

＂New and improved."These words are put in so many marketing campaigns that we tend to accept them as linked.But many new drugs aren't an improvement over the best existing drug for a given condition,and the fast drug-approval processes in recent years have added to the uncertainty about their advantages.

A recent report in the British Medical Journal,"New Drugs;Where Did We Go Wrong and What We Do Better?" analyzed the issue,The authors looked at 216 drugs approved between 2011 and 2017; 152 were newly developed,and 64 were existing medicine approved for new uses. Only 25% offered a major advantage over the established treatment,and fully 58% had no confirmed added benefit to reduce symptoms or improve health-related quality of life.

＂This doesn't mean there's no added benefit,"lead author Wieseler said."It just means we have no positive proof Either we have no studies or have studies not good enough.”Wieseler and her co-authors work for a German agency which evaluates new treatments and advises on whether the country's health care system should pay a premium(补贴）for them.If payers think a new drug isn't better than an existing drug,these agencies will require that hospitals try the cheaper drug first.

Germany's HTA demands trials to prove that a new treatment beats the existing standard. This isn't always practical. For one thing, such studies can be expensive and time-consuming,with no guarantee of success.Secondly,it can discourage companies from attempting to develop new alternatives.This is already happening.Drug developers are increasingly focused on areas where there are no good treatments to compete with,such as rare diseases.

This lack of meaningful data to guide patients is a major point of Wieseler's paper.With accelerated approval,there are more products approved,with a greater amount of uncertainty about risks and benefits. But there are other solutions besides drug trials.One idea is to require postmarket studies to track the effectiveness of newly approved drugs-a step too often neglected.

1.What message does the recent report convey?

A.Improved drugs have advantages over old ones.

B.The approval processes for new drugs are too fast.

C.Many new drugs have no improved advantages.

D.Almost half the drugs approved target the special cases.

2.What's the disadvantage of Germany's HTA trial demands?

A.Making drug companies think of illegal ways to cut cost.

B.Holding companies back from improving existing drugs.

C.Getting patients to depend on the government for support.

D.Pushing companies to try alternatives for existing drugs.

3.What is the best title for the text?

A.The Advantage of Existing Drugs B.The Great Potential of New Drugs

C.People's Preference for New or Old Drugs D.A Dilemma with New Drug Alternatives

高三英语阅读理解中等难度题查看答案及解析